摘要
目的探讨CT联合血清微小RNA-136-5p(miR-136-5p)、肿瘤坏死因子受体相关蛋白1(TRAP1)对非小细胞肺癌(NSCLC)的诊断价值及血清miR-136-5p、TRAP1与预后的关系。方法选取2019年7月至2020年9月该院收治的95例NSCLC患者为NSCLC组,另选取同期该院收治的102例肺部良性病变患者为良性对照组。采用实时荧光定量聚合酶链反应(qPCR)检测血清miR-136-5p水平;采用酶联免疫吸附试验(ELISA)检测血清TRAP1水平;通过Kappa一致性检验分析CT诊断NSCLC与病理诊断的一致性;绘制受试者工作特征(ROC)曲线分析血清miR-136-5p、TRAP1对NSCLC的诊断价值;通过诊断四格表分析CT联合血清miR-136-5p、TRAP1诊断NSCLC的效能;根据随访结果将NSCLC患者分为生存亚组和死亡亚组;通过Kaplan-Meier生存曲线分析血清miR-136-5p、TRAP1水平与NSCLC患者预后的关系。结果Kappa一致性检验结果显示,CT诊断NSCLC与病理诊断的一致性较高(Kappa=0.756,P<0.05)。NSCLC组血清miR-136-5p水平低于良性对照组(P<0.05),血清TRAP1水平高于良性对照组(P<0.05)。血清miR-136-5p诊断NSCLC的曲线下面积(AUC)为0.839,最佳截断值为0.85;血清TRAP1诊断NSCLC的AUC为0.852,最佳截断值为50.40 ng/L。CT与血清miR-136-5p、TRAP1联合(并联)诊断NSCLC的灵敏度为94.74%。死亡亚组血清miR-136-5p水平低于生存亚组(P<0.05),血清TRAP1水平高于生存亚组(P<0.05)。以所有NSCLC患者血清miR-136-5p和TRAP1水平的均值为参考值,将95例患者分为miR-136-5p高表达组(≥0.74)和miR-136-5p低表达组(<0.74)、TRAP1高表达组(≥56.62 ng/L)和TRAP1低表达组(<56.62 ng/L)。miR-136-5p高表达组的生存曲线高于miR-136-5p低表达组(Log-rankχ^(2)=5.659,P=0.017),TRAP1高表达组的生存曲线低于TRAP1低表达组(Log-rankχ^(2)=6.236,P=0.013)。结论CT与血清miR-136-5p、TRAP1联合诊断NSCLC的价值较高,且血清miR-136-5p和TRAP1与NSCLC预后密切相关。
Objective To explore the diagnostic value of CT combined with serum microRNA-136-5p(miR-136-5p)and tumor necrosis factor receptor-associated protein 1(TRAP1)for non-small cell lung cancer(NSCLC),as well as the relationship between serum miR-136-5p and TRAP1 with prognosis.Methods A total of 95 patients with NSCLC admitted and treated in this hospital from July 2019 to September 2020 were selected as the NSCLC group,and 102 patients with benign lung lesions admitted and treated in this hospital during the same period were selected as the benign control group.The level of serum miR-136-5p was detected by real-time fluorescence quantitative polymerase chain reaction(qPCR);the level of serum TRAP1 was detected by enzyme-linked immunosorbent assay(ELISA);the consistency of CT diagnosis of NSCLC and pathological diagnosis was analyzed by Kappa consistency test;the receiver operating characteristic(ROC)curve was drawn to analyze the diagnostic value of serum miR-136-5p and TRAP1 for NSCLC;the diagnostic efficiency of CT combined with serum miR-136-5p and TRAP1 for NSCLC was analyzed through the diagnostic four-cell table;according to the follow-up results,NSCLC patients were divided into the survival subgroup and the death subgroup;the relationship between the serum miR-136-5p and TRAP1 levels with the prognosis of NSCLC patients was analyzed by the Kaplan-Meier survival curve.Results The Kappa consistency test results showed that the consistency of NSCLC CT diagnosis and pathological diagnosis was relatively high(Kappa=0.756,P<0.05).The serum miR-136-5p level in the NSCLC group was lower than that in the benign control group(P<0.05),and the serum TRAP1 level was higher than that in the benign control group(P<0.05).The area under the curve(AUC)of serum miR-136-5p level in the diagnosis of NSCLC was 0.839,and the best cut-off value was 0.85;AUC of serum TRAP1 level in the diagnosis of NSCLC was 0.852,and the best cut-off value was 50.40 ng/L.The sensitivity of CT and serum miR-136-5p and TRAP1 for the combined(parallel)diagnosis of NSCLC was 94.74%.The serum miR-136-5p level in the death subgroup was lower than that in the survival subgroup(P<0.05),and the serum TRAP1 level was higher than that in the survival subgroup(P<0.05).Taking the average values of serum miR-136-5p and TRAP1 levels in NSCLC patients as the reference values,95 patients were divided into the miR-136-5p high expression group(≥0.74)and miR-136-5p low expression group(<0.74),TRAP1 high expression group(≥56.62 ng/L)and TRAP1 low expression group(<56.62 ng/L).The survival curve of the miR-136-5p high expression group was higher than that of the miR-136-5p low expression group(Log-rankχ^(2)=5.659,P=0.017),and the survival curve of the TRAP1 high expression group was lower than that of the TRAP1 low expression group(Log-rankχ^(2)=6.236,P=0.013).Conclusion CT combined serum miR-136-5p and TRAP1 has a high value for diagnosing NSCLC,moreover serum miR-136-5p and TRAP1 are closely correlated to the prognosis of NSCLC.
作者
刘桃桃
寇介丽
刘娜
杨枫
李丹萍
韩君蕊
杨立洲
赵志杰
郝辉
LIU Taotao;KOU Jieli;LIU Na;YANG Feng;LI Danping;HAN Junrui;YANG Lizhou;ZHAO Zhijie;HAO Hui(Department of CT Radiology,Cangzhou Municipal People′s Hospital,Cangzhou,Hebei 061000,China;Department of Clinical Laboratory,Cangzhou Municipal People′s Hospital,Cangzhou,Hebei 061000,China;Department of Oncology,Cangzhou Municipal People′s Hospital,Cangzhou,Hebei 061000,China)
出处
《检验医学与临床》
2025年第9期1165-1169,共5页
Laboratory Medicine and Clinic
基金
河北省沧州市科技局科研重点研发项目(222106039)。
